Repeated administration of cocaine, nicotine and ethanol: effects on preprodynorphin, preprotachykinin A and preproenkephalin mRNA expression in the dorsal and the ventral striatum of the rat.
It is established that dopamine (DA) controls the expression of preprodynorphin (PPDYN), preprotachykinin A (PPT-A) and preproenkephalin (PPE) mRNAs in striatal structures. Since cocaine, nicotine and ethanol enhance extracellular DA concentration, we have examined whether their repeated administration produced common changes in the expression of these mRNAs. Quantitative in situ hybridization histochemistry was performed in rats 2 h after a final challenge subsequent to repeated subcutaneous injections (3 X a day) of cocaine (12.5 mg/kg), nicotine (0.4 mg/kg) for 14 days and ethanol (160 mg/kg) for 7 days. In the dorsal striatum, cocaine produced simultaneous PPDYN and PPT-A mRNA increases without PPE mRNA change whereas nicotine and ethanol produced no modification. After cocaine, PPDYN mRNA was preferentially increased in striatal patch compartment. In the nucleus accumbens, the effects were more complex. In cocaine-treated rats, we measured concomitant increases of PPDYN and PPE mRNA in the rostral pole, an isolated induction of PPT-A mRNA signals in the core without any change in the two shell subregions: the cone and the ventral shell. In contrast, after nicotine and ethanol, the ventral shell was the only accumbal subregion which showed a neuropeptide mRNA alteration, nicotine leading to decreased PPDYN mRNA and ethanol to increased PPT-A mRNA contents. The neuropeptide regulation after chronic treatment with these psychostimulant drugs does not strictly conform to a general DA control scheme in the dorsal and the ventral striatum. The cocaine effects can be clearly distinguished from those of nicotine and ethanol in terms of neuropeptide regulation and striatal subregions affected.
Mathieu-Kia
A M
AM
Laboratoire de Neurochimie-Anatomie, Institut des Neurosciences, CNRS URA 1488, Université Pierre et Marie Curie, Paris, France. anne-marie.mathieu-kia@snv.jussieu.fr
Besson
M J
MJ
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D003042:Cocaine / Q000008:administration & dosage*; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D004334:Drug Administration Schedule; D004399:Dynorphins / Q000187:drug effects / Q000235:genetics*; D004745:Enkephalins / Q000187:drug effects / Q000235:genetics*; D000431:Ethanol / Q000008:administration & dosage*; D017403:In Situ Hybridization; D007279:Injections, Subcutaneous; D008297:Male; D009538:Nicotine / Q000008:administration & dosage*; D009714:Nucleus Accumbens / Q000737:chemistry / Q000187:drug effects; D011498:Protein Precursors / Q000187:drug effects / Q000235:genetics*; D012333:RNA, Messenger / Q000096:biosynthesis* / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D015320:Tachykinins / Q000187:drug effects / Q000235:genetics*
D004745:Enkephalins; D011498:Protein Precursors; D012333:RNA, Messenger; D015320:Tachykinins; C036448:pre-prodynorphin; C044206:preprotachykinin; D000431:Ethanol; D009538:Nicotine; D004399:Dynorphins; C033660:preproenkephalin; D003042:Cocaine